== Platelet count number was measured two times a day during the four-day observational period and treatment with IgM-enriched immunoglobulin (IgM-IVIg); *, p = 0.016 indicates the significant difference between the groups at the end of the observational period, as calculated using Students t-test. The fibrinogen concentration on enrollment did not Rabbit Polyclonal to Bcl-6 differ between the groups (363 mg/dl 52 vs. treat patients with severe sepsis, thereby generating control and IgM-IVIg groups. EA assays, thrombelastometry (ROTEM) and impedance aggregometry (Multiplate) were performed on whole blood. Furthermore, routine laboratory parameters were determined according to units requirements. == Results == Data from 26 patients were included. On day 1, EA was significantly decreased in the IgM-IVIg group following 6 and 12 hours of treatment (0.51 0.06 vs. 0.26 0.07, p<0.05 and 0.51 0.06 vs. 0.25 0.04, p<0.05) and differed significantly compared with the control group following 6 hours of treatment (0.26 0.07 vs. 0.43 0.07, p<0.05). The platelet count was significantly higher in the IgM-IVIg group following four days of IgM-IVIg treatment (200/nl 43 vs. 87/nl 20, p<0.05). The fibrinogen concentration was significantly lower in the control group on day 2 (311 mg/dl 37 vs. 475 mg/dl 47 (p = 0.015)) and day 4 (307 mg/dl 35 vs. 420 mg/dl 16 (p = 0.017)). No differences in thrombelastometric or aggregometric measurements, or inflammatory markers (interleukin-6 (IL-6), leukocyte, lipopolysaccharide binding protein (LBP)) were observed. == Conclusion == Treatment with IgM-enriched immunoglobulin attenuates the EA levels in patients with severe sepsis and might have an effect on septic thrombocytopenia and fibrinogen depletion. Viscoelastic, aggregometric or inflammatory parameters were not influenced. == Trial Registration == clinicaltrials.govNCT02444871 == Introduction == Endotoxin (lipopolysaccharide (LPS)) is a cell wall component of gram-negative bacteria. Elevated LPS concentrations in the bloodstream trigger pathophysiological cascades of sepsis and septic shock [1,2]. With systemic inflammation leading to hypoperfusion of the gastrointestinal tract, which is an enormous reservoir of endotoxin, the presence of LPS in the bloodstream is not necessarily associated with gram-negative infections [35]. Physiologically, endotoxin is usually neutralized by crosslinking MC-Val-Cit-PAB-duocarmycin immunoglobulin class M (IgM), which facilitates phagocytosis and removal. The human polyspecific immunoglobulin preparation, MC-Val-Cit-PAB-duocarmycin Pentaglobin, is usually enriched in immunoglobulin class M (IgM) and thus seems capable of neutralizing bacterial endotoxins. This effect has been exhibited inex vivoexperiments and a randomized controlled clinical trial [6,7]. Though the effects of IgM-enriched immunoglobulins (IgM-IVIg) on endotoxin levels in patients with sepsis have been investigated using the Limulus Amebocyte Lysis test (LAL) [8]. A more recent method of endotoxin measurement, the EA assay (EAA), has not been used to evaluate the effects of IgM-IVIg around the endotoxin levels. EAA has been shown to be more precise and strong than the LAL test [9]. A dysbalance of the pro- and anticoagulation systems, which can lead to a disseminated intravascular coagulation, seems to be a major pathophysiology in septic patients [10,11]. Coagulation markers, such as the international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count and fibrinogen concentration, are altered during systemic inflammation and contamination [1214]. Furthermore, viscoelastic and aggregometric parameters are affected. Adamzik et al. exhibited that parameters of a functional coagulation analysis using rotational thrombelastometry (ROTEM) could predict the 30-day mortality more accurately than standard scoring systems, such as the simplified acute physiology score or the sequential organ failure assessment (SOFA) [15]. The presence of endotoxin bothin vitroandin vivocan modulate several ROTEM parameters to a more procoagulatory state, e.g. decreasing the clotting time (CT) [16,17]. Furthermore, a correlation between the measured endotoxin activity (EA) levels and the functional coagulation parameters, e.g., CT and clot formation time (CFT), has been demonstrated in patients with systemic inflammatory response syndrome (SIRS) or sepsis [18]. In this before-after cohort study, we aimed to investigate the effects of IgM-IVIg (Pentaglobin) therapy on EA in patients with severe sepsis MC-Val-Cit-PAB-duocarmycin or septic shock as a main endpoint. Secondary endpoints focused on the possible effects of IgM-IVIg therapy around the functional coagulation parameters, as measured by ROTEM and multiple electrode aggregometry (MEA), and on the conventional coagulation parameters and the inflammatory markers, such as INR, aPTT, platelet count, fibrinogen concentration, LBP, Interleukin (IL)-6 levels and leukocyte counts. == Materials and Methods == == Study Design and Patients == This single-center before-after cohort study was conducted in a 34-bed tertiary academic surgical ICU from January to June 2013 at the University or college Hospital Frankfurt am Main, Germany. The study complies with the declaration of Helsinki and was approved by the local Scientific and Ethics Review Table (Ethics Committee of the medical faculty of the Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main; filed with the reference number 122/12, at April, 16, 2012). The trial study protocol and a confirmation of the ethical review board stating adherence to the registered trial protocol are attached asS1andS2Figs. This study was registered after.